Autopsy report · NCT02468661

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

“Major challenge for enrollment of participants.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 3 years 2 months before it stopped.
• 23 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Novartis Pharmaceuticals

Sponsor type

Industry

Conditions

Non-Small Cell Lung Cancer

Interventions

INC280 single agent; erlotinib

Participants

23

Sites

32

Countries

Belgium, France, Germany, Italy, Japan, Netherlands, Singapore, South Korea, Spain, United States

Trials that died the same way

• Angiotensin II for Distributive Shock
  “Enrollment Challenges” (88% match in meaning)
• Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma
  “Enrollment challenges, study not feasible” (76% match in meaning)
• Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
  “Difficult to enroll participants” (76% match in meaning)
• Extended Treatment With Vancomycin for Clostridium Difficile Colitis
  “Difficult enrollment” (76% match in meaning)
• The Safety of Transdermal Nicotine Immediately Following an Acute Coronary Syndrome
  “Difficulties with enrollment.” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.